Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 0.84 |
| ▸ | AR | P10275 | 10/20 | 0.84 |
| ▸ | NR3C1 | P04150 | 10/20 | 0.84 |
| ▸ | ESR1 | P03372 | 3/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182440 | 0.94 | PGR (0.87) | PGRARNR3C1ESR1ESR2 | |
| SCHEMBL4182444 | 0.94 | PGR (0.87) | PGRARNR3C1ESR1ESR2 | |
| SCHEMBL4173939 | 0.89 | PGR (0.80) | PGRARNR3C1ESR1ESR2 | |
| SCHEMBL4173947 | 0.89 | PGR (0.80) | PGRARNR3C1ESR1ESR2 | |
| SCHEMBL4176498 | 0.87 | PGR (0.87) | PGRARNR3C1ESR1ESR2 | |
| SCHEMBL4176495 | 0.87 | PGR (0.87) | PGRARNR3C1ESR1ESR2 | |
| SCHEMBL4184226 | 0.87 | PGR (0.80) | PGRARNR3C1ESR1ESR2 | |
| SCHEMBL4184222 | 0.87 | PGR (0.80) | PGRARNR3C1ESR1ESR2 | |
| SCHEMBL4180167 | 0.87 | PGR (1.00) | PGRARNR3C1NR3C2 | |
| SCHEMBL4180169 | 0.87 | PGR (1.00) | PGRARNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796266-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796266-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130261112-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | WYETH LLC | 2013-10-03 | — | — | US | disclosed |
| US-20130261112-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | WYETH LLC | 2013-10-03 | — | — | US | disclosed |
| US-8476262-B2 | Cyanopyrroles | WYETH LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476262-B2 | Cyanopyrroles | WYETH LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8466146-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466146-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130072480-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | WYETH LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072480-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | WYETH LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-7569564-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569564-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090111802-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111802-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-04-30 | — | — | US | disclosed |
| US-7488822-B2 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488822-B2 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070259944-A1 | Indoline derivatives | WYETH (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259944-A1 | Indoline derivatives | WYETH (US) | 2007-11-08 | — | — | US | disclosed |
| US-7253203-B2 | Indoline derivatives | WYETH (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253203-B2 | Indoline derivatives | WYETH (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259944-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | PGR 1/4885AR 11/4885NR3C1 45/4885 |
| US-20130072480-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | PGR, PGRMC2, PGRMC1 | PGR 1/4885AR 97/4885NR3C1 17/4885 |
| US-20130261112-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | PGR, PGRMC2, PGRMC1 | PGR 1/4885AR 97/4885NR3C1 17/4885 |
| US-20090111802-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | PGR, NR5A1, NR3C1 | PGR 1/4885AR 21/4885NR3C1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.